Mugdha explains how the power of connection helps her understand disease on a deeper level.
","transcript":"In middle school when I first learned about genetics, I remember having this spark go off in my brain. Growing up in India, I think I always was attracted to science and math. We had this more regimented curriculum. So, you had to really decide your major before you even started your undergraduate degree and I love computers. So, I chose to go into a pure computer engineering discipline. I discovered this field computational biology and that combined the love for biology with my deep interest in computer science.
\r\nBiology is complex. There is a lot that we still don't understand completely. We try to make sense of biology by using computational methods and integration across many different genetic and genomic data sets. What we are able to do now is look at millions of cells individually basically understand the disease at a level that we couldn't before. We have a big focus on identifying genes that have an underlying genetic association for the disease because we have found that having some genetic association increases your chances of success for that gene to go on to becoming a medicine. And I am naturally attracted towards finding connection. You know one of the things that has been enjoyable for me is learning to Argentinian tango. The beauty about tango is that it is all based on connection - be it with your partner, with yourself, with the people around you, with the floor.
\r\nMy parents have been a really huge inspiration just the way they live their lives, the simplicity, their humbleness their integrity and strong work ethic and dedication towards their profession. They instilled in us this value of not just you know thinking about what you want but also thinking about people around you.
\r\nIn GSK, we have the ability to work together and that's where the promise and the power lies - all these different individuals coming together with their own expertise and driving the drug discovery forward. Really the goal is to use a data-driven approach to identify new medicines for patients.
","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Pal-combining-the-power-of-genetics-and-genomics","title":"Meet Pal: combining the power of genetics and genomics","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/k_7mAYy-Q7M","videoLength":"3:16","thumbnail":{"src":"/media/pfrd2dju/pal-1280.jpg?format=webp&v=1dba2eba874c200","alt":"Photo of Pal","darkModeSrc":"/media/pfrd2dju/pal-1280.jpg?format=webp&quality=50&v=1dba2eba874c200"},"tags":[],"details":"Hear Pal describe how she witnessed first-hand how her work in drug discovery helped a patient.
","transcript":"I still have a birthday card from my best friend in which she says I hope your dreams come true and you become a world-famous scientist. So I think at that age it was really clear to me that I wanted to be a scientist certainly focused on biology and aspects of the human body as well.
\r\nSo the predictive approach really combines the power of both genetics and genomics insights into the understanding of disease and then the power of AI/ML and the work that we do in identifying new drug targets really utilizes all of those aspects. Throughout our understanding of the genetic code, we understand that there are sequences where we lose the function and that's because of a change in the genetic code. So what we try to do in our experiments is to recapitulate that through knocking out a gene which means that we edit the DNA so that it doesn't have the function. So we're trying to reproduce what happens naturally in some individuals that leads to a disease. Historically, we would have been able to do that over the space of a year. Now, we can do it in a couple of weeks and have the data within the month. Means that we can test our hypothesis faster and identify where the next medicine or vaccine will come from to benefit patients.
\r\nSo, I think from an early age, I was really interested in how the human body works. So, trying to understand why my veins looked blue but blood is red, why my cousins had green eyes or why I was taking hay fever medicine and how it actually worked as well. But I did encounter some issues where my school didn't think I was very good at science this really upset me at the time and I'm really grateful to my parents for being so supportive. They encouraged me to think bigger as well to dream about being a scientist to do a PhD, to go to Cambridge - all of those things. I’m very grateful for their support throughout all of that.
\r\nI had the opportunity to work on and co-lead a drug discovery project for several years and that went all the way through into a clinical trial. I was there at the time and it was the most exciting thing to really view in real time that this molecule was going into a person who had a family and all these responsibilities. So, all of those thoughts going through your mind but the immune challenge was then increasing his heart rate. It was making him breathe faster and actually me it was making me through excitement and nerves and all of those emotions also go through the experience with him and then we saw the heart rate decrease because the drug was working in the way that we thought. Seeing that translation from what we had worked on from for several years and how it had translated into a human was phenomenal.
","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Meg-collaborating-to-do-more","title":"Meet Meg: collaborating to do more","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/mxzTpfXNSKs","videoLength":"2:44","thumbnail":{"src":"/media/z0hnuead/meg-1280.jpg?format=webp&v=1dba2eba83b3b70","alt":"Headshot of Meg","darkModeSrc":"/media/z0hnuead/meg-1280.jpg?format=webp&quality=50&v=1dba2eba83b3b70"},"tags":[],"details":"Hear how community fundraising led Meg to her role managing collaborations with GSK partners to help identify targets to get ahead of the disease, together.
","transcript":"So what I'm most excited about at GSK is that we currently have the largest genetic database in the world. That's going to make a difference for the medicines that will be prescribed in the next 10 to 20 years. I work in the Human Genetics and Computational Biology group which is a group of about 125 people focused on leveraging genetic data to identify genes which help us understand the biology of diseases.
\nMy role is to help put together partnerships and collaborations. When I was in my 30s, I started to do some fundraising work at school and at church. And what I learned through that interaction is how important it is to network with people to find out what they're excited about and then focus on what you could do together and that experience is really what highlighted to me that I could perhaps be effective in negotiating collaborations. Currently, we have about 30 collaborations ongoing and we're in the process of negotiating another 10 more.
\nIn my job, I think what I get excited about is when I can find a collaboration that's going to be really impactful for the work that we're doing. So, you know, I find a collaborator that's going to be really innovative to work with or I find a data set that is going to make a difference. The data that we get access to now is allowing us to understand the human body in a way that we haven't been able to before and to use that to correlate to the genetic information. Now we've assembled databases that have several million people and now the state of the data is such that we can really draw novel insights about the biology of diseases.
\nBeing a scientist was actually never on my list of potential jobs. I started out thinking that I wanted to be a doctor as I started to learn about the work, I actually was more interested in the math and computer science aspects than I was in medicine and so I pursued my Ph.D. in statistics.
\nWhat I like most about working at GSK is how it's very dynamic and every day seems like a new challenge or a new and exciting thing and that the people here are so focused on how can we do something for patients and what are the innovative ways that we can do that.
","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Greg-solving-puzzles-is-a-passion","title":"Meet Greg: solving puzzles is a passion","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/rUKva0F-tnY","videoLength":"3:07","thumbnail":{"src":"/media/pn2pludj/greg-1280.jpg?format=webp&v=1dba2eba8533040","alt":"Headshot of Greg","darkModeSrc":"/media/pn2pludj/greg-1280.jpg?format=webp&quality=50&v=1dba2eba8533040"},"tags":[],"details":"For Greg solving puzzles is a passion and part of the job when he’s not writing seminal textbooks.
","transcript":"I've become quite a fan of puzzles. It's a great way to bring people together, solve puzzles together, solve challenges together but in a fun kind of light-hearted way. So it's maybe there's a parallel there with the work that I do. I've always been very interested in science and in discovering medicines. My father worked at a drug company for 35 years and so I kind of got exposed early on to what the kind of the life is like when you're trying to work towards this end and it's always been very exciting to me and I've always wanted to be a part of it.
\r\nWhen I was in graduate school, my adviser at the time, Jeremy Berg, was asked to take on authorship of a book very famous biochemistry textbook written by Lubert Stryer. My sister used it. She was a medical student. She used it in medical school. I used it in graduate school. About 10 years later, it became clear that they needed some additional support in terms of writing the book and so I was asked to be a co-author on the book. It's another way that I feel like I'm influencing younger scientists and kind of making an impact on the community, a larger community.
\r\nOur group was formed about two years ago and it was based on the strategy that GSK has initiated using human genetic data to guide our early work and drug discovery. Human genetically validated targets are twice as likely to be successful in the clinic. We're looking for novelty. We're looking for new medicines that can provide benefit in areas for which there are no medications available. To really be in that position, you really need to be innovative. You really need to think outside a box and think creatively about these problems. I think that starts at the very beginning in terms of using genetics and AI/ML for example. The amount of data that's available to us really gives us a new window into diseases that we once thought would be too difficult to treat or too challenging or we didn't understand the patient populations all that well.
\r\nIt's a very exciting time and GSK has a number of great partnerships that we've developed with UK Biobank and Fingen and also our exclusive partnership with 23andMe. That's really given us an opportunity to collaborate with really world-class organizations and take advantage of their prowess in terms of getting that data. We're actually providing the first in the lab test of these ideas. It's still pretty ground-breaking.
\r\nWhat GSK is trying to do in terms of tying that in with target identification, picking the right disease populations, picking the right diseases to pursue. Getting medicines to patients quicker, I think is really the goal and I think you can really play a very important role in that.
","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Giovanna-being-in-the-golden-age-for-molecular-biology","title":"Meet Giovanna: being in the golden age for molecular biology","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/zpIZo0uzZ08","videoLength":"1:07","thumbnail":{"src":"/media/vuddqofl/giovanna16x9-web-image-copy.jpg?format=webp&v=1dba2eba8b6d410","alt":"Giovanna","darkModeSrc":"/media/vuddqofl/giovanna16x9-web-image-copy.jpg?format=webp&quality=50&v=1dba2eba8b6d410"},"tags":[],"details":"Giovanna talks about the joy of scientific discovery and why teamwork in everything in the vast new world of cell biology.
","transcript":"This is a golden era of molecular biology. It's like being on a fast train and it's getting faster all the time.
","modules":[{"type":"rich-text","text":"Being a pioneer
\nThere is something so exciting about being the first person to see something. It’s like the explorers who reached the North Pole for the first time, planting that flag in the snow, knowing nobody else has ever been there before. I get such an energy from that feeling, and no matter how many times things haven’t gone right along the way, that single moment pays off all the failures.
\nJust like those explorers couldn’t do it alone, I have had amazing people around me through my whole journey. I love building teams; collaboration is fundamental to scientific discovery, and I really believe we can all be outstanding. I think there’s a bit of luck involved in getting to a position like mine. Obviously there’s hard work, that goes without saying, but I didn’t have a clear path; there were lots of twists and turns.
\nAs a kid I was very shy and introverted, certainly not ambitious; if you’d told me then that I’d end up as a senior director at a company like GSK, I would have laughed! There have been a few times when I hesitated or lacked confidence, but I’ve always had people around me to say “you can do it!’ Being open to opportunities and not being afraid are the key, so you can take your chances when they come along, even if the timing might not be perfect. And having the resources to take the next step is so important – that’s why working at GSK is great, because we’ve got the right talent to think about those big questions.
\nMaking a difference
\nI always liked thinking about big problems; I almost went into philosophy but I loved the rigour of science. I grew up with really strong values about family, solidarity, having a purpose and doing work that has a benefit. My mom was very into cultural enrichment and my dad was an engineer with a strong belief in sustainability, at a time when those themes weren’t as popular as they are now. Both of my brothers are in applied science too – one is an engineer and the other is working on drought resistant plants.
\nI really connected with wanting to help patients when I did my PhD in Bologna, Italy. I had to walk through the hospital, past all the patients, to get to my lab. Every day I saw with my own eyes people with disease and it was tangible that the work I generated could help those people. Even today, all the work we do in our lab is in partnership with local hospital clinics, so I still have that really strong sense of connection that I used to have walking through those hospital wards.
\nWhen I started out in Biology it wasn’t the most exciting science. That all changed while I was doing my PhD and suddenly, with data so readily available across the world in real time, and all the game changing technologies emerging around genome sequencing, I found myself in the middle of a new golden era of molecular biology.
\nRight now, it’s like being on a fast train, and it’s getting faster all the time. If we get it right, that train is heading towards a better understanding of outcomes, and that in turn may bring us to the position of being able to cure people in a more effective way, with better rationale and better cures. In the end, that will help all of us.
\nFamily values
\nHeidelberg, Germany is a great international city to live in, full of scientists and interesting people, but I still carry a strong Italian identity even after 20 years of being away. I love taking my children back to visit my family where I grew up in Puglia, in the south of Italy. People go there on holiday for the warm air and the beautiful beaches and olive groves. The culture is always with me; I love good food, good wine, good conversation. Things worth taking time over; that’s very Italian!
\nI’m a single mom so keeping up with my children’s busy lives takes a lot of time but I love being with them, and it makes me so happy to see how proud of me they are. In the past, I’ve had this side of me that didn’t know when something was good enough. I can still be a perfectionist, but I have learned with time to be aware of those traits, and spending time with my children helps me embrace my imperfections! I also learned from them how encouraging diversity is fundamental to feeling closer to people.
\nBig picture thinking
\nI think science was good preparation for parenting! You have to learn to live with the feeling that you might not get the result for a long time into the future, and you have to be prepared to all learn together.
\nMany times in my work I’ve gone down a path that didn’t take me anywhere, and had to start over and invest all that energy again. I worked in genetics, then virology, then gene expression, then immunology and oncology. Every time you start from scratch, and psychologically that has a price, but I’ve learned to be resilient and concentrate on the things that work. That’s a lesson I owe to science, the understanding that most of the things you do might not pan out.
\nTo make it in science, you need to learn to take the excitement of that one thing that does work out to compensate for the other 99 times when you’re frustrated! It helps being able to see the big picture – I love to go deep into the science, but I’ve always got that philosophical side of me that’s thinking ahead and strategically, and never getting stuck in the detail of the moment.
\nPushing the horizon
\nThe horizons we’re reaching for with GSK are very ambitious and we are closely collaborating with academia, since these are global challenges for the whole scientific community. We are looking at cutting edge technologies and everything that’s coming out is new. My team is developing new methods to measure what is happening inside a single cell. This is really game changing in the whole field of biology, but particularly for characterising immune cells; to be able to look at a single cell in a multi-dimensional way is revolutionising our understanding of disease and of how drugs affect cells in the human body.
\nOur aim is to analyse the molecular status of a disease sample and compare it with a healthy cell, find the processes that are altered and try to modulate those processes to restore them to something more like the healthy cell. We’ve got to the point where we have the tools to do that; now starts the big work of science, and we’re right in the middle of it. That is so exciting, to see how we can bring it all together and find out what the future holds.
\nLooking ahead, science fiction might not be science fiction anymore. That’s my mission, that for any symptom there is an effective way of identifying the cause and better tools to intervene so that we can prevent a lot of suffering, increase quality of life, and reduce sickness and death. It’s a real global effort, and we are all learning together.
","useGreyBackground":false,"fullWidth":false}]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Euan-using-technology-in-drug-discovery","title":"Meet Euan: using technology in drug discovery","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/EvncZCkCHuI","videoLength":"3:17","thumbnail":{"src":"/media/lv3dbq45/euan-1280.jpg?format=webp&v=1dba2eba8d6df30","alt":"Headshot of Euan","darkModeSrc":"/media/lv3dbq45/euan-1280.jpg?format=webp&quality=50&v=1dba2eba8d6df30"},"tags":[],"details":"Curiosity keeps Euan’s wheels turning as he and his team identify new targets for drug discovery.
","transcript":"I'm motivated by two things. The first is a strong scientific curiosity and the second is to apply that in a way that's going to be of benefit to patients. From a very early age I was really interested in how things worked and I I always used to take every toy I had apart and occasionally got them back together again in working order so I think when we got to school and started getting biology lessons and started understanding how life worked that was incredibly exciting.
\r\nI work in functional genomics which is the name suggest is about the study of gene function but doing it on a really large scale so we can use gene editing technologies such as CRISPR to adjust the activity of genes either up or down or remove them all together and we can do that in multiple cell types we can use that to study what those genes are doing in that cell type either a but also by adding in drugs we can look at what those genes do to the response of that particular drug. So we're really involved in identifying the new targets that will enter the pipeline. They will then go into drug discovery into clinical trials and eventually through to be approved medicines. We have a lot of access to genetic databases either through publicly available data or through specific collaborations that we've got with the likes of 23andMe FinnGen and UK Biobank.
\r\nWe can then take that information and design functional experiments which we can run in house either using our own scientists or through our collaborative network. So, what I'm excited about with the technologies that we've got now is the ability to run these at whole genome scale and as an example of that we run an experiment recently. With and without drug treatment, with experimental replicates, with multiple guides for every gene, we end up with a data set that's running into the tens of millions of data points, so it truly is vast. Even though we can run these huge experiments we can't run the experiments of the scale that we'd like to so what we want to be able to do is run the entire genome versus the entire genome. We're talking about 20,000 genes x 20,0000 genes. So it's 400 million interactions that we're looking at. That experiment is not possible at the moment. So that's where it becomes really important to have our colleagues in artificial intelligence and machine learning.
\r\nAnd by running real experiments, feeding the data from that into their models, their models get better and better at predicting. So, it allows us to make that impossible experiment possible. I've loved cycling for a long time ever since I got my first BMX at age eight or so and I think cycling is pretty much whatever you want it to be you can just go out and turn the pedals and just lose yourself in your thoughts or you can push yourself physically to the limit but it's also incredibly sociable so we've got a group of people that we ride with that are all either GSK or XGSK people so we're quite a like-minded bunch Because we're like minded it's a good opportunity sometimes away from meetings just to thrash out an idea or a problem.
","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Jeremy-my-drive-is-to-fix-whats-wrong-with-the-world","title":"Meet Jeremy: my drive is to fix whats wrong with the world","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/YbQ9VQO3F5E","videoLength":"1:14","thumbnail":{"src":"/media/c5gkmq4v/jeremy-16-9-web-image.jpg?format=webp&v=1dba2eba8edc290","alt":"Jeremy","darkModeSrc":"/media/c5gkmq4v/jeremy-16-9-web-image.jpg?format=webp&quality=50&v=1dba2eba8edc290"},"tags":[],"details":"Jeremy tells us about his cutting-edge work with synthetic lethality and what drives him to make the world a better place.
","transcript":"I think a lot of us who are the grandchildren of Holocaust survivors carry a drive to fix what's wrong with the world.
\r\nI'm really proud that I'm working on something now with GSK which has a potential application with great general benefit to humanity.
","modules":[{"type":"rich-text","text":"Searching for meaning
\nMy mother’s family were Polish Jews who survived the holocaust, escaping to the Soviet Union when the rest of their families were wiped out during the second world war. My mother was born in Poland after the war ended; her family escaped the Iron Curtain in 1957, became refugees in West Germany, then made their way to the United States, settling in Massachusetts.
\nI think a lot of Holocaust survivors shared a very intense desire to claw their way back and build a world that’s better than the one they lived through, along with a kind of idealism about living a life with meaning. Often I think the path to that meaning was through an obsession with education, knowledge and understanding. That was certainly a fire in my mother’s belly. I guess I was born into the right family when it came to curiosity – I loved dinosaurs at 4, black holes at 10 and just always wanted to know more!
\nI think a lot of us who are the grandchildren of those survivors carry that drive to fix what’s wrong with the world in some way. My sister is an associate professor of psychology, studying Alzheimers, and I’m really proud that I am working on something now with GSK which has a potential application with great general benefit to humanity.
\nSynthetic lethality
\nThe main project here in the AI-ML team Israel is to do with synthetic lethality, and this is where the work is really cutting edge. We’re looking at enormous amounts of data to try and predict how to make therapies that do no harm at all to healthy parts of the body, while being specifically and potently lethal to the cancerous parts. That is how we begin to develop a strategy for synthetic lethality.
\nOur aim is to analyse huge datasets from individual cells to identify potential new targets in terms of genes or other aspects of molecular cell biology to go after with pharmaceuticals. The idea is that, if we can find enough patterns in the data, we can pinpoint vulnerabilities in particular cancer cells and choose the right weapon in our arsenal to attack. If we can make it work, it has the potential to transform our strategy for fighting cancer.
\nOur biggest project is named after an ancient Jewish recipe for creating incense; it’s very specific about getting the ingredients exactly right in perfect combination, which felt right for what we are trying to do. The difficulty with looking at individual genes is the numbers are so huge - even if you just wanted to look at different combinations of, say, three genes being on or off, you’re talking about millions of experiments, which we haven’t got time or resource for. That’s why we need machine learning, to predict which are the best next experiments both to give us the information we need to make the system better and to discover the synthetic combinations for those Achilles heels in cancer cells. That means finding all the combinations of manipulations of gene activity that might be effective at targeting some cells and leaving others unharmed. It’s a challenging problem, but we have a lot of talent in the team to tackle it.
\nSharing knowledge
\nMy path has been a bit of an eccentric orbit. I started off in biochemistry, did a PhD in physics, then started my lab at MIT as a theoretical biophysicist looking at how life emerged. That brought me into machine learning, because we were trying to model what happened with different combinations of particles. And then I got pulled back towards biology and came to GSK in 2019, carrying with me a new enthusiasm for machine learning and really excited about applying it to biological problems.
\nThis is the best possible thing I could have done, both in terms of moving into more applied biomedical sciences and for my family. It’s been such great timing, because I get to bring in perspectives from other fields and try to really do something innovative and different. I’m learning more every month than I have for years.
\nWhile I was at MIT, the novelist Dan Brown read about my work and he asked me out to lunch one day to tell me he had a character in his novel ‘Origin’ that had my name and did the same work. I actually wrote a piece in the Wall Street Journal to clarify something important - that character was unwilling to think about the broader implications of his work, and I clearly don’t feel that way! After that I wrote my own book, ‘Every Life is on Fire’, about the boundary between life and non-life, and I brought some poetry and passages from religious texts into it, to show my belief that all scientific inquiries carry along with them a set of philosophical questions and implications that extend outside the realm of science.
\nFinding a home
\nI first visited Israel while I was studying at Oxford. My identity as a scientist was a big part of how I thought of myself and who I was, but I was reaching the point where trying to understand the world only through science was like taking a black and white photograph of a rainbow; highly accurate in some ways, but missing some of the aspects that define it and make it real. I became fascinated with the very rich and enthralling intellectual pursuit of studying Judaism. I had a very visceral reason to love it, because of my family history, and I got very drawn in, so that was where I decided I wanted to plant my spiritual feet.
\nWhile I was in Oxford I was influenced by the writings of Jonathan Sacks, who was the Chief Rabbi of the UK at that time; that’s part of why I chose to become an ordained orthodox rabbi. I really enjoy finding meaning from our religious texts involving science and discovery, and teaching them in our community.
\nMy wife is a scientist as well - she studied Biology and we were at MIT together. We always dreamed of moving to Israel with our three sons, so we could immerse ourselves in the Jewish community and all the rites and practices that go along with that.
\nMoving to Israel with GSK feels like a hand in glove fit with the work that needed to be done and the place I wanted to be with my family. It really is one of those instances where two different aspects of my life worked together in beautiful concert, and I just feel so grateful that GSK has been a part of helping that to happen. Israel is a major talent center, both in biotechnology and machine learning, so there was a very good strategic reason to start to build this team here; they’re GSK’s first R&D group in Israel and are already doing outstanding work. That makes me really proud.
","useGreyBackground":false,"fullWidth":false}]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Melanie-focused-on-helping-more-patients-with-hepatitis-B","title":"Meet Melanie: focused on helping more patients with hepatitis B","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/Rg-Edku_KcU","videoLength":"3:19","thumbnail":{"src":"/media/my1bxstj/melanie-paff.jpg?rxy=0.48,0.21041666666666667&format=webp&v=1dba2eba900ae50","alt":"Melanie Paff","darkModeSrc":"/media/my1bxstj/melanie-paff.jpg?rxy=0.48,0.21041666666666667&format=webp&quality=50&v=1dba2eba900ae50"},"tags":[],"details":"Melanie leads a team committed to addressing one of the most significant global health threats: hepatitis B. Find out what inspires her and why she thinks being a scientist is one of the coolest jobs ever.
","transcript":"Being a scientist is the coolest job ever. Though it's not about being right or wrong, it's about telling the truth and when you tell the truth, you still learn something and you grow from that and you can apply that to the next thing.
\nSo, I grew up in a household where professional sports had always been very important. My father was a professional baseball player. If I heard my dad say one time I probably heard him say it a thousand - never ever walk on the field with the intention to just not lose - that success is always honed by discipline and challenge and learning continually honing your craft as you go along.
\nI'm a Medicines Development Leader here at GSK. Chronic hep B is inherently an immune dysfunction disease. It's a very silent disease. It's a very quiet disease. People don't talk about it. The majority of people actually that are walking around with hep B right now don't even know that they have it. By the time you realise that it's an issue you're pretty late in the progression of the disease.
\nPeople that are infected will either get an acute infection which is cleared immediately by your immune system or your immune system becomes dysfunctional over time and your immune system is no longer able to handle the virus and It develops chronicity and the virus is actually quite smart. It sends out specific proteins to help make that happen. So, what we're trying to do with our therapies going forward is to reverse that process and allow the immune dysfunctionality to be cured, you want to be able to inhibit the virus from replicating, no new baby viruses. You want to get rid of the immuno-tolerant proteins that the virus makes and then lastly, you want to be able to stimulate the immune system to make sure that your tired, dysfunctional immune system is starting to work again.
\nOne of the things I'm particularly proud of in this programme is our ability to reach back in and really understand the patient's point of view. We actually have formed a hep B patient counsel which provides us with insights from the patient's point of view around the design and conduct of our clinical trials. It's probably the most complicated programme that I've ever worked on but the effect that you have at the end of the day and the promise that you have at the end of the day is amazing.
\n","modules":[]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Katie-using-big-data-to-help-more-patients","title":"Meet Katie: using big data to help more patients","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/XhaX_plQLc0","videoLength":"1:10","thumbnail":{"src":"/media/323b1nfc/katie-16x9-web-image-copy.jpg?format=webp&v=1dba2eba9187c10","alt":"Katie ","darkModeSrc":"/media/323b1nfc/katie-16x9-web-image-copy.jpg?format=webp&quality=50&v=1dba2eba9187c10"},"tags":[],"details":"
Katie opens up about her journey to big data with GSK and how standing at the top of a mountain helps her discover new perspectives.
","transcript":"If we're successful with how we're thinking differently about these technologies, there could be a paradigm shift and people might start doing their jobs really differently.
\r\nI think that's pretty cool.
","modules":[{"type":"rich-text","text":"Reach for the stars
\nIn a way, the job we’re trying to do with big data is like the Apollo space mission. I've always been really interested in that 1960’s era of space exploration - they went to the moon, it’s so cool! What’s compelling is that sense of an impossibly huge mission, and sometimes what we are trying to do with data and drug discovery at GSK feels like a similarly daunting problem.
\nThe Apollo program had to create so many technologies, from the control systems and the rockets to the materials that didn't exist before. Completely different sets of people had to come together to work towards that common goal and create or transform individual fields or disciplines, otherwise it would just have been a fancy rocket that didn’t go anywhere. I think if we want to create something totally transformative in big data, we must have all those pieces in place too, build new systems and technologies and think about the problems completely differently. That’s what we’re trying to do with the team here at GSK.
\nMy hope is that our collective vision will get us to this exciting new place. Even though each team or department are working on different projects, our focus on technology and thinking differently about how we use big data means we’re all travelling forward together. It’s going to be amazing. I think there will be a paradigm shift and people will be doing their jobs differently. And that is almost as cool as going to the moon!
\nEngineering solutions
\nIt’s exciting to be in San Francisco right now, but I have a love-hate relationship with the whole Silicon Valley tech scene. It's inspiring to be around a lot of people who have really big ideas and make things happen, and there's this energy and velocity to life in the Bay Area that's really cool. But for a small-town kid I sometimes look around and think it’s all a little crazy!
\nIt’s comforting that I’m working on something so big and so important. When I first went into biomedical engineering I was really motivated by how interesting and impactful the problems were. You never have to explain to anyone why the problem you're working on is important, because people just innately understand that we need to be able to treat disease and we need to be able to improve the medical field for patients.
\nIn my team, we’re figuring out how we can take advantage of the exponential rise in data. We don’t just want to jump on the data train and ingest data that everyone else is generating, we want to develop our own data strategy. This approach has the potential to be transformative, first by improving our current processes, but it also opens up a space where we can be really imaginative about what the future of drug development could look like. It might be a complete paradigm shift, but if we really let ourselves blue sky dream for a bit, where could this take us? We don’t know yet, but we’re charting the course right now.
\nRiding the wave
\nI never made a conscious decision to go into big data; I started off in classic biomechanics, then started getting interested in genomics, and it seemed like the next step was always a little bigger, and a little different, and I was on the cusp of that. I had to keep learning something new to move forward, and it just happened to be at that cutting edge of where the technology was going. I feel grateful that the timing was right for me to ride this current wave of machine learning.
\nAs I learned more about science and engineering, I wanted to be able to make as much of a difference as I could across the board. Often when you get to PhD studies, it tunnels narrower and deeper, whereas I felt this work opened up at the end, and that was really compelling to me.
\nI'm very grateful to be where I am. One of the things I really like about GSK is we have a really good mix of skills and experience in teams. GSK values long and continuously evolving careers but also injects new ideas and new energy with younger, more diverse talent. I think GSK is unique in that.
\nGrowing up curious
\nSome of my favorite high school Science teachers were fantastic women who had advanced degrees - a couple of them had industry careers as engineers and scientists and then returned to teaching, which was so inspiring.
\nI really enjoy teaching – for a while I thought I wanted to be a professor, for the buzz of seeing things click for someone else, when they can join the dots and understand something in a way they didn’t before. I’ve been surprised how many opportunities I have at GSK to bring people along for the ride in that way. When I look at where we were a year ago compared to now, there’s been a huge change in interest and awareness.
\nI grew up dancing from the time I was three, so I spent a lot of time at the studio. I taught dance classes through high school and college, and studied choreography. I love the patterns and the complexity of dance, the way it feels to dedicate yourself to that intensive practice and inspire others too. As well as being creative with dance, I was curious about a lot of different things and my family was outdoorsy – we used to spend the summers camping and exploring, with a lot of freedom.
\nFresh perspective
\nNo matter where I’ve lived or what stage of life I’ve been at, the serenity of the mountains has always been something I’ve sought out and loved. To look around and see a view I haven’t seen, a new perspective; I find that peaceful, but also exciting.
\nI love being totally unplugged. A lot of times in the mountains there just isn’t a signal, there isn’t wi-fi, there isn’t a way to use your phone. Sometimes it’s nice to be off the grid.
\nI climbed Grand Teton in Wyoming with my dad when I was in grad school, which was definitely the most memorable climb I’ve done. It was one of those objective climbs. It's not super huge, but I knew it was going to be a challenge. I got to spend time with my dad and do something together, and get this amazing feeling at the end.
\nI think in some ways the real reason to climb a mountain is for the challenge of it, the experience of setting a goal, completing a task. It’s hard work, but you really get the reward at the end with this beautiful view. Standing on top of a mountain helps you see things differently.
","useGreyBackground":false,"fullWidth":false}]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Shihyun-the-joy-of-scientific-discovery","title":"Meet Shihyun: the joy of scientific discovery","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/0ryVHT4wiY0","videoLength":"1:15","thumbnail":{"src":"/media/l4jnmern/shihyun-16x9-web-image-copy.jpg?format=webp&v=1dba2eba93070e0","alt":"Shihyun","darkModeSrc":"/media/l4jnmern/shihyun-16x9-web-image-copy.jpg?format=webp&quality=50&v=1dba2eba93070e0"},"tags":[],"details":"“Viruses are mind-boggling!” Shihyun You, Senior Director, Infectious Diseases Research Unit, on her endless fascination with living things, the joy of scientific discovery with world leading scientists, and why a complicated family history with the hepatitis B virus helped her embrace GSKs smart risk-taking approach to finding a potential cure.
","transcript":"Viruses are mind-boggling aren't they?
\r\nThey're like little mind-boggling aliens really. I think the world is endlessly fascinating.
\r\nI just find myself looking around and thinking wow this is incredible with all those new science and new discoveries.
\r\nHow do we all get here?
","modules":[{"type":"rich-text","text":"Lucky escape
\nWhen I was a child, hepatitis B was still endemic where I grew up in Seoul, South Korea. Now they have vaccines, but in those days many were infected. It’s mostly a self-limiting, acute infection in adults, but for children whose immune systems are still developing it can lie dormant, not causing symptoms until many years later – about 90% of cases in children develop chronic hepatitis B virus (HBV) infection. I was one of the 10% who did not, which means my immune system somehow naturally produced antibodies to get rid of the virus. My brothers weren’t so lucky – both of them were infected. At the time I was too young to understand the consequences, but now I am very grateful that I was spared. I think the question of why and how my body did that and my brothers’ couldn’t is always in the back of my mind.
\nWe lost my older brother, a talented animation artist, in late March 2001 after complications following a liver transplant due to decompensated cirrhosis. My younger brother is under long term treatment which works well to prevent things getting worse, but it isn’t a cure. At the moment the only option for hepatitis B patients is to take medication for life. I didn’t begin my life in science to work on this disease, but now I do feel I have a purpose, to try and find a cure which might help my brother and all the other people out there with chronic hepatitis B. It’s a very complicated disease, so we don’t really imagine that one treatment option or drug will cure it. Likely it will be some combination of multiple mechanisms. Within GSK I’m responsible for thinking strategically about what areas of biology it makes sense to explore, and how we can validate those combinations.
\nWorking together
\nI was lucky that growing up as a girl in South Korea, my family were always supportive of my ambitions. My grandma was pretty old fashioned culturally, always making sure my brothers had the best to eat, that sort of thing, but my mom definitely encouraged me to do what I wanted to do, because she hadn’t had the chance in her generation. Considering that probably back then what would have been expected of me was to get married and start a family, it’s pretty amazing that my parents were so behind me moving abroad to pursue my career.
\nAt certain times of life, having support is so important. I remember one of my colleagues at GSK when I first started as a biology leader was so good at listening to everyone. In meetings he always made a point of asking my opinion and providing me a platform to speak. I try to do the same thing for my teams. Whoever they are, I want them to know someone is listening.
\nCutting edge science
\nI started specialising in molecular biology while I was still in South Korea; it was such an exciting field with genetic engineering emerging and I realised if I wanted to learn more I needed to move abroad. I moved to the US to do a PhD, and during that time I happened to rotate into the virology lab, where they were trying to answer a question about Dengue virus. That was the first time I worked on viruses, and it was really mind-boggling. They’re like aliens, really! Working in that lab was where I had my first experience of the joy of scientific discovery. I had an idea, and I did an experiment – back then we used radio-isotopes so I was putting my X-ray film into the developer in the darkroom and waiting to see what came out. I remember turning on the light and seeing all these bands on the film; it was such an amazing feeling of ‘yes, it worked!’, and definitely a little addictive!
\nAfter that, for my post-doctoral training, I worked with Professor Charlie Rice, who won the Nobel prize in 2020 for his work on hepatitis C. The diseases have the same name but they’re really different, so knowledge on one doesn’t translate to the other, but working with high calibre scientists enabled me to learn so much. While I was there, I discovered a bit of artistic talent – putting together PowerPoint presentations in a graphic way to simplify and clarify complicated information. My older brother was an artist and my mom wanted to be a painter, and I really found my creative side in presenting scientific stories.
\nFinding a balance
\nI’m looking forward to travelling when the world opens up again, enjoying some good food and good drink and exploring new places. I have been cooking a lot during the pandemic - I love getting everything prepared and putting together all the ingredients, following the method and seeing what comes out. My homemade lasagne bolognese took two days, but the look on everyone’s face when I brought it to the table made it all worthwhile. It’s a bit like running an experiment – it’s been several years since I was in the lab so maybe I’m missing it!
\nMy husband and I are a good mix; he keeps me grounded because he’s rather spontaneous and laid back. He had testicular cancer in college and maybe having that surgery and experience so young changed his mindset. I understand that – soon after my brother’s funeral I did a skydive, which was totally out of character. I guess I was proving a point, but I won’t be doing anything like that again! I prefer hanging out at home with my furbabies. We have a dog and three cats - one of them is named Alex, after the main character of the animation movie my late brother worked on. I got him when I came back to the States right after the funeral and he’s 21 years old now. I think of my brother a lot, and at some moments it really strikes me how young he was when we lost him to chronic hepatitis B. That’s why I’ve made trying to help other people with the disease my goal.
\nBeing curious
\nI’m not a risky person – I’ll never jump out of a plane again! – but I’m not afraid of failure. If I have a question, I don’t worry about whether things might not work out, I need to know I’ve tried.
\nI think to be successful in science you have to be curious. Being open-minded and following a path can lead you to discover something new, even if it’s just the next question. I’ve learned to recognise when curiosity is leading me down a useful path; the key is keeping the end in mind. We are lucky now to have big data as well as experience to help us make those decisions, so it’s more like smart risk taking, making sure our curiosity is leading us to a situation where we can help the patient.
\nWhen I stop and think about it, everything in life is amazing. The human body we’re trying to help cure, these viruses we study. They are completely remarkable; so small they are just basically a few proteins. I think the world is endlessly fascinating. I just find myself looking around and thinking, ‘this is incredible, how did we get here?’
","useGreyBackground":false,"fullWidth":false}]},{"href":"/en-gb/company/outstanding-people/innovating-together/#Meet-Nancy-igniting-change-innovation-for-patients-living-with-Respiratory-Syncytial-Virus-RSV-","title":"Meet Nancy: igniting change & innovation for patients living with Respiratory Syncytial Virus (RSV)","publishDate":"2022-06-14T00:00:00Z","youtubeUrl":"https://youtube.com/embed/VmdJ9qfB39g","videoLength":"1:29","thumbnail":{"src":"/media/h0ep1wig/gsk-op-16x9nancy-8.jpg?format=webp&v=1dba2eba9433590","alt":"Nancy outstanding people","darkModeSrc":"/media/h0ep1wig/gsk-op-16x9nancy-8.jpg?format=webp&quality=50&v=1dba2eba9433590"},"tags":[],"details":"Nancy and her team lead on the development of a vaccine for Respiratory Syncytial Virus (RSV), a common, highly contagious virus that can cause serious respiratory illness in children and older adults. Find out why her father’s illness was a big motivation and why she’s excited to be challenging the status quo with vaccine development.
","transcript":"The impact we can have on older adults’ lives is so big, is so positive, and that’s why I was so keen to take up this position with GSK.
","modules":[{"type":"rich-text","text":"RSV (Respiratory Syncytial Virus) is common and highly contagious virus that can cause serious respiratory illness affecting the lung and breathing passages in children and in people with weakened immune system such as older adults. RSV is not well recognised; it has similar symptoms to other respiratory infections like flu and COVID-19, and there is no routine testing for older adults. That means it’s difficult to know just how widespread it is, and a lack of specific treatment means it can have a serious impact on quality of life.
\nMore than 20 years ago, my father was diagnosed with a B-cell lymphoma and Parkinson’s disease. Consequently, he suffered from serious co-morbidities. I saw first-hand how each time he got an infection, even with a virus causing mild disease, the level of activities he could manage would reduce. That led to a gradual decline over the years because he never quite got back to his baseline level in terms of health and quality of life. That’s why I was so keen to take up this position with GSK.
\nLeading vaccine development for older adults was exactly the opportunity I’d been looking for because I knew we could have a big impact on many lives. Our aim is to help patients keep their independence as long as possible. One way to do that is to prevent them from getting those infections that might be mild in younger adults, but dangerous for others. That’s my motivation to drive forward the development of vaccines for older adults.
\nIn the past, a lot of people thought vaccines were just for children. Within GSK we’ve understood for many years the importance of protecting older adults against infections, but the whole world started to take notice when the COVID-19 pandemic hit. Suddenly everyone realised the importance of vaccines. I thought ‘Wow! They finally realise we’re doing really important work for global health.’ Before that, I don’t think people realised the huge impact vaccines could have on older adult’s lives and quality of life.
\nAnother thing everyone realised during the COVID-19 pandemic was the impact of doing things faster and at scale. My family has a background in business - my grandmother was a pioneer who refused to accept the status quo for women at that time, which was to be at home with the family. She ran two businesses, innovating and leading. That seeded my ambition to forge a path where I can make the most impact, and I’ve always tried to apply that principle to everything I do - whether it’s science or strategy or teamwork - to make improvements and analyse how we can make things better.
\nI have three daughters, all of whom have inherited my spirit - and my grandmother’s - of not accepting the status quo and instigating changes that will make a difference now, and in the future. I’m so proud when they speak against something they believe is wrong, encourage diversity or protect the vulnerable - that’s something everyone in my family values.
\nMy husband is an engineer, and my oldest daughter is studying medicine. My father was a teacher, so he had an impact on children’s education, and my mother has impacted in a different way by supporting my father through his long illness, ensuring he maintained his freedom at home. My mother made his quality of life possible, and that was a great gift to him and to society.
\nI started off with a degree in pharmacy and, although it was interesting, I wanted to do something more innovative. So, for my PhD I developed a radiopharmaceutical for visualising amyloid proteins involved in Alzheimer’s disease. I loved being at the forefront of discovery. Around that time my father discovered he had a rare blood cell cancer involving the same amyloid proteins.
\nHaving studied them, I understood how bad it was, even if he didn’t realise at the time. Luckily, I was able to reach out to the scientific community I’d become part of when pursuing my PhD and he joined a cutting-edge clinical study to test a stem cell treatment. It was an incredibly difficult year, but he recovered. That’s when I realised that the science I was doing in academia was interesting, but I wanted to do something with a bigger impact on society. Having that business mindset helped me understand the importance of bringing a lot of different disciplines together and always looking for ways to do things faster, more efficiently or better. That’s how I ended up at GSK.
\nSome vaccines we develop combine different technologies with the intention of meeting the specific needs of the older adult immune system. Firstly, an antigen provides a targeted immune response towards a specific target of the pathogen, for example a surface protein to enhance the inhibition of viral replication. In younger adults this might be enough, but our hypothesis is that diseases can be more severe in older adults because they have a weaker immune response, so we also include an adjuvant which is intended to bring T-cell levels up, which may be an important component of the immunity needed to prevent severe respiratory disease.
\nWhat people don’t understand is that you need an innovative culture to bring this sort of benefit to so many people. The failure rates of new medicines and new vaccines are huge, and you can’t help people without taking smart risks and following the science. That’s why I joined GSK, because I realised how many people our medicines could potentially impact. No matter which strategy we are developing, our cross-functional development team always keeps in mind the impact to patients and what is best for the patient. That culture is embedded in our decision making.
\nAnother important aspect of GSK’s culture is pushing boundaries, taking smart risks and not being afraid to fail, because that’s when new discoveries happen. At home I love reading books and listening to music, shopping, and keeping fit with Zumba, but I like to be creative at work as well. Currently, I’m trying to get every person who’s been involved in this vaccine together, virtually, to learn a dance routine. I want to show the world that we’re not afraid to fail, but we can get ahead by working together.
\nThe world of vaccines is becoming increasingly competitive. Since the COVID-19 pandemic, we’re now going head-to-head with new companies who are entering the vaccines space for the first time, and that’s giving us a whole new dimension. It’s exciting to be thinking strategically about something that will bring great value not just for GSK but for the health and life quality of older adults. That’s the impact we want to make.
","useGreyBackground":false,"fullWidth":false}]}]},"id":8391,"docCheckLogout":null,"pageType":"outstandingPeopleSeriesPage","languageCode":"en-GB","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-gb/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Outstanding people","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null},{"text":"Innovating together","href":"/en-gb/company/outstanding-people/innovating-together/","openInNewWindowText":null}]},"pageName":"Innovating together","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-gb/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":true,"text":"Global"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark mode","tooltipText":"Switch to dark mode to head towards a more sustainable world together. More info
"},"globalSiteLink":null,"locationSelector":{"text":"Change location","href":"/en-gb/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science magazine","url":"/en-gb/behind-the-science-magazine/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-gb/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-gb/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"Outstanding people","url":"/en-gb/company/outstanding-people/","nodes":[{"title":"Great place to work","url":"/en-gb/company/outstanding-people/great-place-to-work/","nodes":[],"isActive":false},{"title":"Meet our veterans","url":"/en-gb/company/outstanding-people/meet-our-veterans/","nodes":[],"isActive":false},{"title":"Working together","url":"/en-gb/company/outstanding-people/working-together/","nodes":[],"isActive":false},{"title":"My GSK story","url":"/en-gb/company/outstanding-people/my-gsk-story/","nodes":[],"isActive":false},{"title":"Innovating together","url":"/en-gb/company/outstanding-people/innovating-together/","nodes":[],"isActive":true}],"isActive":true},{"title":"GSK at a glance","url":"/en-gb/company/gsk-at-a-glance/","nodes":[],"isActive":false},{"title":"History and heritage","url":"/en-gb/company/history-and-heritage/","nodes":[],"isActive":false},{"title":"Board of Directors and Executive Committee","url":"/en-gb/company/board-of-directors-and-leadership-team/","nodes":[],"isActive":false},{"title":"Board information","url":"/en-gb/company/board-information/","nodes":[],"isActive":false},{"title":"Governance","url":"/en-gb/company/governance/","nodes":[{"title":"Committees","url":"/en-gb/company/governance/committees/","nodes":[],"isActive":false},{"title":"Shareholders","url":"/en-gb/company/governance/shareholders/","nodes":[],"isActive":false},{"title":"Sarbanes-Oxley Act 2002","url":"/en-gb/company/governance/sarbanes-oxley-act-2002/","nodes":[],"isActive":false},{"title":"Compliance","url":"/en-gb/company/governance/compliance/","nodes":[],"isActive":false}],"isActive":false},{"title":"Policy positions","url":"/en-gb/company/policy-positions/","nodes":[],"isActive":false},{"title":"Codes, standards and reports","url":"/en-gb/company/codes-standards-and-reports/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Our purpose, strategy and culture","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=100&v=1dba2ec0bc1e680","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=50&v=1dba2ec0bc1e680"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-gb/innovation/","nodes":[{"title":"Our leading scientists","url":"/en-gb/innovation/our-leading-scientists/","nodes":[{"title":"Dr Tony Wood","url":"/en-gb/innovation/our-leading-scientists/tony-wood/","nodes":[],"isActive":false},{"title":"Dr Sabine Luik","url":"/en-gb/innovation/our-leading-scientists/sabine-luik/","nodes":[],"isActive":false},{"title":"Dr Hesham Ahmed Abdullah","url":"/en-gb/innovation/our-leading-scientists/hesham-abdullah/","nodes":[],"isActive":false},{"title":"Dr Kaivan Khavandi","url":"/en-gb/innovation/our-leading-scientists/kaivan-khavandi/","nodes":[],"isActive":false}],"isActive":false},{"title":"Research and development approach","url":"/en-gb/innovation/research-and-development-approach/","nodes":[],"isActive":false},{"title":"Pipeline","url":"/en-gb/innovation/pipeline/","nodes":[],"isActive":false},{"title":"Therapeutic areas","url":"/en-gb/innovation/therapeutic-areas/","nodes":[{"title":"Respiratory, immunology and inflammation","url":"/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-gb/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/en-gb/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-gb/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"Tech","url":"/en-gb/innovation/technologies/","nodes":[],"isActive":false},{"title":"Clinical trials at GSK","url":"/en-gb/innovation/trials/","nodes":[{"title":"Provision of unapproved medicines for unmet medical needs","url":"/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/","nodes":[],"isActive":false},{"title":"Data transparency","url":"/en-gb/innovation/trials/data-transparency/","nodes":[],"isActive":false},{"title":"Representative clinical studies","url":"/en-gb/innovation/trials/representative-clinical-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"Partnering with GSK","url":"/en-gb/innovation/partnerships/","nodes":[{"title":"Supported studies","url":"/en-gb/innovation/partnerships/supported-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"R&D locations","url":"/en-gb/innovation/rd-locations/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Our leading scientists","image":{"src":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=100&v=1dc651e856734f0","alt":"Tony Wood","darkModeSrc":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=50&v=1dc651e856734f0"},"link":{"text":"Featured section","href":"/en-gb/innovation/our-leading-scientists/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-gb/products/","nodes":[{"title":"Product areas","url":"/en-gb/products/our-product-areas/","nodes":[],"isActive":false},{"title":"Products A-Z","url":"/en-gb/products/products-a-z/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Innovation","image":{"src":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe22d650","alt":"Lab technician leaning against wall","darkModeSrc":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe22d650"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/","openInNewWindowText":null}},{"text":"GSKPro for healthcare professionals ","image":{"src":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe35c210","alt":"Two scientists on orange background","darkModeSrc":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe35c210"},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-gb/responsibility/","nodes":[{"title":"Access","url":"/en-gb/responsibility/access/","nodes":[],"isActive":false},{"title":"Global health and health security","url":"/en-gb/responsibility/global-health-and-health-security/","nodes":[{"title":"Global health","url":"/en-gb/responsibility/global-health-and-health-security/global-health/","nodes":[],"isActive":false},{"title":"Health security","url":"/en-gb/responsibility/global-health-and-health-security/health-security/","nodes":[],"isActive":false},{"title":"Using our science for global health","url":"/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/","nodes":[],"isActive":false},{"title":"Improving access to healthcare","url":"/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/","nodes":[],"isActive":false},{"title":"Africa Open Lab","url":"/en-gb/responsibility/global-health-and-health-security/africa-open-lab/","nodes":[],"isActive":false}],"isActive":false},{"title":"Environment","url":"/en-gb/responsibility/environment/","nodes":[{"title":"Climate","url":"/en-gb/responsibility/environment/climate/","nodes":[],"isActive":false},{"title":"Freshwater","url":"/en-gb/responsibility/environment/freshwater/","nodes":[],"isActive":false},{"title":"Land","url":"/en-gb/responsibility/environment/land/","nodes":[],"isActive":false},{"title":"Oceans","url":"/en-gb/responsibility/environment/oceans/","nodes":[],"isActive":false},{"title":"Materials and waste","url":"/en-gb/responsibility/environment/materials-and-waste/","nodes":[],"isActive":false},{"title":"Health system sustainability","url":"/en-gb/responsibility/environment/health-system-sustainability/","nodes":[],"isActive":false}],"isActive":false},{"title":"Inclusion","url":"/en-gb/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-gb/responsibility/ethical-standards/","nodes":[{"title":"Working with third parties","url":"/en-gb/responsibility/ethical-standards/working-with-third-parties/","nodes":[],"isActive":false},{"title":"Public policy and patient advocacy","url":"/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","nodes":[],"isActive":false},{"title":"Human rights","url":"/en-gb/responsibility/ethical-standards/human-rights/","nodes":[],"isActive":false},{"title":"Use of animals","url":"/en-gb/responsibility/ethical-standards/use-of-animals/","nodes":[],"isActive":false},{"title":"Engaging with healthcare professionals","url":"/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false}],"isActive":false},{"title":"Product governance","url":"/en-gb/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-gb/responsibility/grants-and-donations/","nodes":[],"isActive":false},{"title":"Charitable investments ","url":"/en-gb/responsibility/charitable-investments/","nodes":[],"isActive":false},{"title":"Responsibility reports","url":"/en-gb/responsibility/responsibility-reports/","nodes":[{"title":"Reports archive","url":"/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"FEATURED SECTION","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}},{"text":"Our policy positions","image":{"src":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe9b61b0","alt":"GSK orange texture","darkModeSrc":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe9b61b0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/company/policy-positions/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Investors","url":"/en-gb/investors/","nodes":[{"title":"Why invest in GSK?","url":"/en-gb/investors/why-invest-in-gsk/","nodes":[],"isActive":false},{"title":"Quarterly results","url":"/en-gb/investors/quarterly-results/","nodes":[],"isActive":false},{"title":"Financial reports","url":"/en-gb/investors/financial-reports/","nodes":[{"title":"Annual Report 2025","url":"/en-gb/investors/financial-reports/annual-report-2025/","nodes":[],"isActive":false},{"title":"Corporate reports archive","url":"/en-gb/investors/financial-reports/corporate-reports-archive/","nodes":[],"isActive":false}],"isActive":false},{"title":"Responsible business","url":"/en-gb/investors/responsible-business/","nodes":[],"isActive":false},{"title":"Speeches and presentations","url":"/en-gb/investors/speeches-and-presentations/","nodes":[],"isActive":false},{"title":"Science publications","url":"/en-gb/investors/science-publications/","nodes":[],"isActive":false},{"title":"Events calendar","url":"/en-gb/investors/events-calendar/","nodes":[],"isActive":false},{"title":"Dividend and share price","url":"/en-gb/investors/dividend-and-share-price/","nodes":[{"title":"GSK share price","url":"/en-gb/investors/dividend-and-share-price/gsk-share-price/","nodes":[],"isActive":false},{"title":"Share price calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calendar","url":"/en-gb/investors/dividend-and-share-price/dividend-calendar/","nodes":[],"isActive":false}],"isActive":false},{"title":"Analyst consensus","url":"/en-gb/investors/analyst-consensus/","nodes":[],"isActive":false},{"title":"Stock exchange announcements","url":"/en-gb/investors/stock-exchange-announcements/","nodes":[{"title":"London (RNS)","url":"/en-gb/investors/stock-exchange-announcements/london-rns/","nodes":[],"isActive":false},{"title":"London (RNS) inside information","url":"/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/","nodes":[],"isActive":false},{"title":"New York (SEC)","url":"/en-gb/investors/stock-exchange-announcements/new-york-sec/","nodes":[],"isActive":false},{"title":"Sign up for announcements","url":"/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/","nodes":[],"isActive":false}],"isActive":false},{"title":"Shareholder information","url":"/en-gb/investors/shareholder-information/","nodes":[{"title":"Manage your shares","url":"/en-gb/investors/shareholder-information/manage-your-shares/","nodes":[],"isActive":false},{"title":"Annual General Meeting","url":"/en-gb/investors/shareholder-information/annual-general-meeting/","nodes":[],"isActive":false},{"title":"General Meeting","url":"/en-gb/investors/shareholder-information/general-meeting/","nodes":[],"isActive":false},{"title":"Annual Governance Meeting","url":"/en-gb/investors/shareholder-information/annual-governance-meeting/","nodes":[],"isActive":false},{"title":"Corporate sponsored nominee service","url":"/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/","nodes":[],"isActive":false},{"title":"Our ADR programme","url":"/en-gb/investors/shareholder-information/adr-programme/","nodes":[],"isActive":false},{"title":"Asset reunification - Georgeson ","url":"/en-gb/investors/shareholder-information/asset-reunification-georgeson/","nodes":[],"isActive":false},{"title":"Share scam alert","url":"/en-gb/investors/shareholder-information/share-scam-alert/","nodes":[],"isActive":false},{"title":"Privacy notice for ordinary shareholders","url":"/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/","nodes":[],"isActive":false},{"title":"FAQs","url":"/en-gb/investors/shareholder-information/shareholder-faqs/","nodes":[],"isActive":false}],"isActive":false},{"title":"Corporate actions","url":"/en-gb/investors/corporate-actions/","nodes":[{"title":"Consumer Healthcare Demerger","url":"/en-gb/investors/corporate-actions/consumer-healthcare-demerger/","nodes":[],"isActive":false},{"title":"Consumer Healthcare Joint Venture","url":"/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/","nodes":[],"isActive":false},{"title":"Agreement to acquire TESARO","url":"/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/","nodes":[],"isActive":false}],"isActive":false},{"title":"Debt investors","url":"/en-gb/investors/debt-investors/","nodes":[],"isActive":false},{"title":"Investor contacts","url":"/en-gb/investors/investor-contacts/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Press releases","image":{"src":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc6f12bb0","alt":"Lab machinery","darkModeSrc":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc6f12bb0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/media/press-releases/","openInNewWindowText":null}},{"text":"Our pipeline","image":{"src":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc701f490","alt":"Case of vials","darkModeSrc":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc701f490"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/pipeline/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-gb/media/","nodes":[{"title":"Press releases","url":"/en-gb/media/press-releases/","nodes":[],"isActive":false},{"title":"Media contacts","url":"/en-gb/media/media-contacts/","nodes":[],"isActive":false},{"title":"Media library","url":"/en-gb/media/media-library/","nodes":[],"isActive":false},{"title":"Zantac litigation","url":"/en-gb/media/zantac-litigation/","nodes":[],"isActive":false},{"title":"GSK's position on Flovent","url":"/en-gb/media/gsks-position-on-flovent/","nodes":[],"isActive":false},{"title":"Our social media","url":"/en-gb/media/social-media/","nodes":[],"isActive":false},{"title":"Podcasts","url":"/en-gb/media/podcasts/","nodes":[],"isActive":false},{"title":"RSS feeds","url":"/en-gb/media/rss-feeds/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"Spotlight on","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-gb/careers/","nodes":[{"title":"Search jobs","url":"/en-gb/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Featured careers","url":"/en-gb/careers/featured-careers/","nodes":[{"title":"A career in data","url":"/en-gb/careers/featured-careers/a-career-in-data/","nodes":[],"isActive":false}],"isActive":false},{"title":"Life at GSK","url":"/en-gb/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-gb/careers/experienced-professionals/","nodes":[{"title":"Business operations","url":"/en-gb/careers/experienced-professionals/business-operations/","nodes":[],"isActive":false},{"title":"Engineering at GSK ","url":"/en-gb/careers/experienced-professionals/engineering/","nodes":[],"isActive":false},{"title":"Global supply chain","url":"/en-gb/careers/experienced-professionals/global-supply-chain/","nodes":[],"isActive":false},{"title":"Sales and marketing","url":"/en-gb/careers/experienced-professionals/sales-and-marketing/","nodes":[],"isActive":false},{"title":"Research and development","url":"/en-gb/careers/experienced-professionals/research-and-development/","nodes":[{"title":"Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)","url":"/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/","nodes":[],"isActive":false},{"title":"Genomic sciences","url":"/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/","nodes":[],"isActive":false}],"isActive":false},{"title":"Technology","url":"/en-gb/careers/experienced-professionals/technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-gb/careers/early-careers/","nodes":[{"title":"Application process","url":"/en-gb/careers/early-careers/application-process/","nodes":[],"isActive":false},{"title":"Apprentice programmes","url":"/en-gb/careers/early-careers/apprentice-programmes/","nodes":[],"isActive":false},{"title":"Internships and placements","url":"/en-gb/careers/early-careers/internships-and-placements/","nodes":[],"isActive":false},{"title":"Graduate programme","url":"/en-gb/careers/early-careers/graduate-programme/","nodes":[{"title":"Business operations","url":"/en-gb/careers/early-careers/graduate-programme/business-operations/","nodes":[],"isActive":false},{"title":"Engineering","url":"/en-gb/careers/early-careers/graduate-programme/engineering/","nodes":[],"isActive":false},{"title":"Manufacturing & supply","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/","nodes":[],"isActive":false},{"title":"Commercial ","url":"/en-gb/careers/early-careers/graduate-programme/commercial/","nodes":[],"isActive":false},{"title":"Research & development","url":"/en-gb/careers/early-careers/graduate-programme/research-development/","nodes":[],"isActive":false},{"title":"Digital & tech","url":"/en-gb/careers/early-careers/graduate-programme/digital-tech/","nodes":[],"isActive":false},{"title":"Manufacturing sciences & technology","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Post graduate opportunities","url":"/en-gb/careers/early-careers/post-graduate-opportunities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/early-careers/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans","url":"/en-gb/careers/veterans/","nodes":[],"isActive":false},{"title":"Our global and regional hubs","url":"/en-gb/careers/our-global-and-regional-hubs/","nodes":[],"isActive":false},{"title":"How we hire","url":"/en-gb/careers/how-we-hire/","nodes":[{"title":"Fraudulent internet recruitment activities","url":"/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/how-we-hire/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"Spotlight on","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}},{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"Spotlight on","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}}]}],"skipToContent":"Skip to content","skipToSearch":"Skip to search","typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-gb/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector.
\n\n
© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nRegistered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
","modernSlaveryStatement":{"name":"Modern Slavery Act Statement 2025","url":"/media/5ladhmeu/modern-slavery-act-statement-2025.pdf","fileExtension":"PDF","fileSize":"187.7KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Linkedin","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"http://twitter.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK X page","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://bsky.app/profile/gsk.bsky.social/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"","customIcon":null,"showPopupMenu":false,"type":"Bluesky"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Facebook page","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK YouTube Channel","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"/en-gb/media/rss-feeds/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Visit GSK RSS feeds","customIcon":null,"showPopupMenu":false,"type":"Rss"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"Locations selector","href":"/en-gb/locations/","openInNewWindowText":null},{"text":"Social media directory","href":"/en-gb/media/social-media/","openInNewWindowText":null},{"text":"GSKPro for healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-gb/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-gb/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-gb/responsibility/","openInNewWindowText":null},{"text":"Investors","href":"/en-gb/investors/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-gb/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},{"text":"Partnerships","href":"/en-gb/innovation/partnerships/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-gb/contact-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-gb/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-gb/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-gb/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-gb/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-gb/privacy-notice/general","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-gb/sitemap/","openInNewWindowText":null}],"continueToLink":{"text":"GSK at a glance","href":"/en-gb/company/gsk-at-a-glance/","openInNewWindowText":null,"continueTo":""},"legalApprovalText":""},"sharing":{"description":"Learn how our people are using the science of the immune system, human genetics and advanced technologies to find treatments for patients","og":[{"property":"og:title","content":"Innovating together"},{"property":"og:description","content":"Learn how our people are using the science of the immune system, human genetics and advanced technologies to find treatments for patients"},{"property":"og:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530"},{"property":"og:url","content":"https://www.gsk.com/en-gb/company/outstanding-people/innovating-together/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Innovating together"},{"name":"twitter:description","content":"Learn how our people are using the science of the immune system, human genetics and advanced technologies to find treatments for patients"},{"name":"twitter:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530"},{"name":"twitter:url","content":"https://www.gsk.com/en-gb/company/outstanding-people/innovating-together"}]},"stickyShare":{"href":"https://www.gsk.com/en-gb/company/outstanding-people/innovating-together/","pageTitle":"Innovating together","shareText":"Share series","newTabLinkText":"Opens in a new window","shareOnTwitterText":"Share on Twitter","shareOnLinkedInText":"Share on LinkedIn","shareOnFacebookText":"Share on Facebook"},"exitSitePreferences":{"popupEnabled":false,"title":"","texts":"","continueText":"Continue","cancelText":"Cancel","exclusionUrls":[]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=100&v=1dbf4b05a4e6470","alt":"Gsk Logo","darkModeSrc":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=50&v=1dbf4b05a4e6470"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":null,"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://www.gsk.com/en-gb/company/outstanding-people/innovating-together/"},"tealiumSettings":{"enabled":true,"data":""},"entryPopup":null,"protectedPage":false,"schema":null,"modules":[{"type":"outstanding-people-watch-other-series","heading":"Watch other series","allSeriesHref":"/en-gb/company/outstanding-people/","allSeriesHrefTitle":"Explore other series","videoText":"video","videosText":"videos","series":[{"href":"/en-gb/company/outstanding-people/great-place-to-work/","episodeCount":11,"seriesTitle":"Great place to work","thumbnailImage":{"src":"/media/50xmp15k/sddefault-2.jpg?format=webp&v=1dba2eba6f2b5e0","alt":"smiling woman in a pink shirt sitting on a couch","darkModeSrc":"/media/50xmp15k/sddefault-2.jpg?format=webp&quality=50&v=1dba2eba6f2b5e0"}},{"href":"/en-gb/company/outstanding-people/meet-our-veterans/","episodeCount":4,"seriesTitle":"Meet our veterans","thumbnailImage":{"src":"/media/jb4bxf5e/sddefault-4.jpg?format=webp&v=1dba2eba805d390","alt":"Meet our veterans","darkModeSrc":"/media/jb4bxf5e/sddefault-4.jpg?format=webp&quality=50&v=1dba2eba805d390"}},{"href":"/en-gb/company/outstanding-people/working-together/","episodeCount":4,"seriesTitle":"Working together ","thumbnailImage":{"src":"/media/45ybz4ze/gsk_precisionpoint_1280x720_trust_nicola.jpg?format=webp&v=1dba2eba9939f80","alt":"Nicola headshot","darkModeSrc":"/media/45ybz4ze/gsk_precisionpoint_1280x720_trust_nicola.jpg?format=webp&quality=50&v=1dba2eba9939f80"}},{"href":"/en-gb/company/outstanding-people/my-gsk-story/","episodeCount":8,"seriesTitle":"My GSK story","thumbnailImage":{"src":"/media/xshi3rvo/gsk_twist_small_1280x720_employee_hewan.jpg?format=webp&v=1dba2eba963dcf0","alt":"GSK Twist Small 1280X720 Employee Hewan (1)","darkModeSrc":"/media/xshi3rvo/gsk_twist_small_1280x720_employee_hewan.jpg?format=webp&quality=50&v=1dba2eba963dcf0"}}]}]}